These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25841703)

  • 1. Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia.
    Vijay A; Bazazi AR; Yee I; Kamarulzaman A; Altice FL
    J Subst Abuse Treat; 2015 Jul; 54():29-36. PubMed ID: 25841703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients.
    Kelly SM; Brown BS; Katz EC; O'Grady KE; Mitchell SG; King S; Schwartz RP
    Am J Drug Alcohol Abuse; 2012 May; 38(3):233-8. PubMed ID: 22242643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.
    Shah PA; Sohler NL; López C; Fox AD; Cunningham CO
    J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study.
    Ayres R; Ingram J; Rees A; Neale J; Beattie A; Telfer M
    Subst Abuse Treat Prev Policy; 2014 Nov; 9():44. PubMed ID: 25407020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of sharing of needles and syringes among people who inject drugs in Dhaka city, Bangladesh.
    Hemel MM; Reza MM; Shafiq TK; Kabir MI; Rana AM; Khan SI
    J Infect Dev Ctries; 2021 Oct; 15(10):1497-1506. PubMed ID: 34780373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
    Betts KS; Chan G; McIlwraith F; Dietze P; Whittaker E; Burns L; Alati R
    Addiction; 2016 Jul; 111(7):1214-23. PubMed ID: 26857811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. African American patients seeking treatment in the public sector: characteristics of buprenorphine vs. methadone patients.
    Mitchell SG; Kelly SM; Gryczynski J; Myers CP; Jaffe JH; O'Grady KE; Olsen YK; Schwartz RP
    Drug Alcohol Depend; 2012 Apr; 122(1-2):55-60. PubMed ID: 21962726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia.
    Mukherjee TI; Pillai V; Ali SH; Altice FL; Kamarulzaman A; Wickersham JA
    Int J Drug Policy; 2017 Sep; 47():144-152. PubMed ID: 28652072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
    Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
    Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia.
    Bazazi AR; Wickersham JA; Wegman MP; Culbert GJ; Pillai V; Shrestha R; Al-Darraji H; Copenhaver MM; Kamarulzaman A; Altice FL
    Contemp Clin Trials; 2017 Aug; 59():1-12. PubMed ID: 28479216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid maintenance therapy in Switzerland: an overview of the Swiss IMPROVE study.
    Besson J; Beck T; Wiesbeck G; Hämmig R; Kuntz A; Abid S; Stohler R
    Swiss Med Wkly; 2014; 144():w13933. PubMed ID: 24706398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
    Lugoboni F; Zamboni L; Cibin M; Tamburin S;
    Eur Addict Res; 2019; 25(1):10-19. PubMed ID: 30625491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
    Fingerhood MI; King VL; Brooner RK; Rastegar DA
    Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.